SEC Form 4 · accession 0001731122-18-000087
Enochian Biosciences Inc · ENOB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mark Dybul
Director
Period of report
Sep 19, 2018
Accepted (ET)
Sep 27, 2018 · 1:04 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001527728
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option to Purchase Common StockF1 | $5.74 | Sep 19, 2018 | A | 5,226 | A | Feb 28, 2019 | Sep 19, 2028 | Common Stock | 5,226 | 12,834 | D |
Explanation of responses
- F1On September 19, 2018, Dr. Dybul was granted an option to purchase shares of common stock of Enochian Biosciences, Inc. valued at $30,000, said option to vest on the anniversary date of Dr. Dybul's appointment as director of Enochian, exercisable at the closing market price per share on the date of the grant.